Natco Pharma
Natco Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Natco Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Natco Pharma Ltd trades at a P/E of 11.16× and P/B of 1.83×.
Valuation
Profitability
Growth
Financial Health
Natco Pharma Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Natco Pharma Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Natco Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Natco Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Natco Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,930.03 Cr and reported EPS of ₹79.19.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,202 | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| Other Income | 40 | 130 | 107 | 104 | 99 | 105 | 128 | 355 | 298 |
| Total Income | 2,242 | 2,225 | 2,022 | 2,156 | 2,044 | 2,812 | 4,127 | 4,784 | 4,376 |
| Cost of Goods Sold (COGS) | 411 | 354 | 382 | 511 | 561 | 627 | 717 | 690 | 691 |
| Gross Profit | 1,791 | 1,740 | 1,533 | 1,541 | 1,384 | 2,080 | 3,282 | 3,740 | 3,388 |
| +Operating Expenses | 863 | 946 | 951 | 935 | 1,120 | 1,144 | 1,531 | 1,544 | 1,951 |
| EBITDA | 928 | 795 | 583 | 606 | 264 | 936 | 1,751 | 2,196 | 1,437 |
| +Non-Operating Expenses | 82 | 100 | 121 | 130 | 160 | 178 | 206 | 259 | 243 |
| Profit Before Tax (PBT) | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 |
| +Tax Expense | 192 | 182 | 111 | 137 | 32 | 147 | 285 | 408 | 119 |
| Profit After Tax (PAT) | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 |
| Earnings Per Share (EPS) | 37.74 | 35.24 | 25.31 | 24.18 | 9.31 | 39.20 | 77.51 | 105.26 | 79.20 |
| Diluted Shares Outstanding (Nos.) | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| +Additional Disclosures | 1,760 | 1,745 | 1,818 | 2,098 | 2,452 | 2,580 | 3,185 | 3,156 | 3,910 |
| Sales Growth % | — | -4.88 | -8.57 | 7.16 | -5.23 | 39.20 | 47.72 | 10.77 | -7.93 |
| YoY Sales Growth % | — | -4.88 | -8.57 | 7.16 | -5.23 | 39.20 | 47.72 | 10.77 | -7.93 |
| Material Cost % | 18 | 16 | 17 | 18 | 27 | 18 | 13 | 12 | 15 |
| Employee Cost % | 15 | 17 | 20 | 20 | 23 | 18 | 13 | 13 | 17 |
| Other Cost % | 24 | 28 | 30 | 25 | 35 | 24 | 25 | 21 | 31 |
| OPM % | 42 | 38 | 30 | 30 | 14 | 35 | 44 | 50 | 35 |
| Tax % | 22 | 22 | 19 | 24 | 16 | 17 | 17 | 18 | 8 |
| Profit Growth % | — | -7.59 | -28.69 | -3.43 | -61.57 | 320.76 | 94.09 | 35.66 | -24.68 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 862 | 714 | 483 | 489 | 121 | 772 | 1,565 | 1,961 | 1,230 |
Natco Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Natco Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Natco Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Natco Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Natco Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Natco Pharma Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Natco Pharma exhibits a robust Return on Equity (ROE) of 28.00%, signifying efficient capital utilization and strong profitability. Coupled with a high Return on Capital Employed (ROCE) of 32.80%, this indicates excellent operational efficiency and asset management.
The company boasts a remarkably low Price-to-Earnings (P/E) ratio of 8.73, suggesting that the stock might be undervalued relative to its earnings. This presents a potentially attractive entry point for investors seeking value.
Natco Pharma's impressive Operating Profit Margin (OPM) of 44.60% highlights its ability to effectively manage costs and generate substantial profits from its operations. This strong margin underscores the company's pricing power and operational efficiency.
Despite recent stock price volatility, promoter holding remains strong at 49.5%, indicating confidence in the company's future prospects and a reduced risk of hostile takeovers or significant share dilution.
Natco Pharma's strong financial health, indicated by its 28.00% ROE and 32.80% ROCE, positions it well to pursue strategic acquisitions or expand into new therapeutic areas, driving future growth.
What can break it.
While quarterly profits show growth, there's significant volatility in sales (-2.47%) and profit (-28.10%) figures across quarters. This inconsistency in performance presents a risk to consistent returns for investors.
Although the debt-to-equity ratio is low at 0.04, the absolute debt level of ₹279 crore might still pose a constraint on future growth, especially during economic downturns or unexpected financial challenges.
The stock price has experienced considerable volatility, swinging between a high of ₹1505 and a low of ₹660 in the past year. This high degree of price fluctuation introduces significant investment risk.
While promoter holding is relatively high, the public shareholding (around 30.56%) is substantial. This could lead to increased price volatility driven by market sentiment and speculative trading.
Intense competition from larger, well-established pharmaceutical players like Sun Pharma (Market Cap ₹411665 Cr) and Divi's Lab (Market Cap ₹173033 Cr) could limit Natco Pharma's market share and pricing power.
What would change my mind.
Trim if P/E re-rates above 15. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 8.24. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Natco Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Natco Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Natco Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Natco Pharma Ltd — derived from the live tape, not yesterday's close.
Natco Pharma Ltd last traded at ₹889 with an intraday range of ₹876.1–₹910 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹889.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 975.10 | +86.10 | +9.69% |
| R3 | 941.20 | +52.20 | +5.87% |
| R2 | 925.60 | +36.60 | +4.12% |
| R1 | 907.30 | +18.30 | +2.06% |
| PIVOT | 891.70 | 2.70 | 0.30% |
| CURRENT | 889.00 | — | — |
| S1 | 805.60 | -83.40 | -9.38% |
| S2 | 839.50 | -49.50 | -5.57% |
| S3 | 857.80 | -31.20 | -3.51% |
| S4 | 873.40 | -15.60 | -1.75% |
NATCOPHARM is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 876.1 ~ 910
Trading Inside opening range
Natco Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Natco Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Natco Pharma Ltd stood at 39.9% of traded volume, against a 20-day average of 40.4%.
Natco Pharma announcements: results, concalls, ratings, M&A.
Filings Natco Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Natco Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 129 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Natco Pharma Limited has informed the Exchange about Transcript
Press Release
Natco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive…
Copy of Newspaper Publication
Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Annual Audited Financial Results for the quarter and year ended…
Analysts/Institutional Investor Meet/Con. Call Updates
Natco Pharma Limited has informed the Exchange about Link of Recording
Analysts/Institutional Investor Meet/Con. Call Updates
Natco Pharma Limited has informed the Exchange about FY26 Earnings Presentation
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Natco Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Natco Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Natco Pharma insider activity below tracks 15 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr | ₹1,017.31 |
| PRAGNYA RAO DONTHINENI | Insider | 10 Jun 2025 | buy | +100 | ₹86,500 | ₹865.00 |
| SANJAY NANNAPANENI | Insider | 26 Mar 2025 | buy | +2.87 L | — | — |
| VENKATA SATYA SWATHI KANTAMANI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
| RAJEEV NANNAPANENI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
Natco Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Natco Pharma has declared, sequenced by announce and record date.
Natco Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Natco Pharma Ltd: business, sector, key facts.
What Natco Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Natco Pharma Ltd operates in the Healthcare, listed as NSE: NATCOPHARM, BSE: 524816.
NATCO Pharma Limited is a global pharmaceutical company with a diverse business model encompassing the development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates. Their operations span India, the United States, and other international markets, showcasing a significant reach in the pharmaceutical industry.
A core component of NATCO's business is the production and sale of finished dosage formulations targeting a wide range of therapeutic areas. These formulations are particularly strong in oncology, addressing various cancers including those affecting the blood, liver, kidney, lung, brain, breast, and ovary. Beyond oncology, they also offer products for cardiology and diabetology, specifically targeting conditions like hypertension, stable angina, and congestive heart failure (CHF).
In addition to finished formulations, NATCO Pharma is a significant player in the API market. They manufacture APIs across several therapeutic categories, mirroring the focus of their finished dosage formulations. These categories include oncology, central nervous system treatments, pain management solutions, and cardiovascular care medications. This vertical integration, controlling both API and formulation production, gives them a strategic advantage in the market.
Further diversifying their portfolio, NATCO Pharma provides specialized products in orthopedics, notably bisphosphonates in both oral and injectable forms. They also cater to gastroenterology needs with novel drugs targeting chronic hepatitis B and C. Furthermore, the company offers contract manufacturing services, leveraging their manufacturing expertise to provide services for other pharmaceutical entities.
Beyond human pharmaceuticals, NATCO Pharma extends its reach into the agrochemical sector. They offer a range of solutions for biological pest management, providing tools to control insects, diseases, and weeds across various crops. This expansion into agrochemicals diversifies their revenue streams and demonstrates their adaptability within the broader chemical industry.
Questions investors ask about Natco Pharma Ltd (NATCOPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Natco Pharma Ltd (NATCOPHARM)?
The current share price of Natco Pharma Ltd (NATCOPHARM) is ₹889. Today, the stock has gained by ₹5.50 (0.62%), trading in a range of ₹876.1 to ₹910. The stock opened at ₹884.9 with a trading volume of 10,20,729 shares.
02Is Natco Pharma Ltd stock a good investment for long-term?
Natco Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,930.03 crores, P/E ratio of 11.16, ROE of 16.85%, and ROCE of 32.80%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Natco Pharma Ltd stock?
The 52-week high price of Natco Pharma Ltd (NATCOPHARM) is ₹1,226.8, while the 52-week low is ₹789. Currently trading at ₹889, the stock is 22.8% away from its 52-week low and 27.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Natco Pharma Ltd stock at the current price?
Whether to buy Natco Pharma Ltd stock at ₹889 depends on multiple factors. The stock is currently trading with a P/E ratio of 11.16 and P/B ratio of 1.83. Today's performance shows a gain of 0.62%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Natco Pharma Ltd and when is the next dividend?
Natco Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹889, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Natco Pharma Ltd?
Natco Pharma Ltd's key financial metrics include: P/E Ratio: 11.16, P/B Ratio: 1.83, ROE: 16.85%, ROCE: 32.80%, Dividend Yield: 0.00%, EPS: ₹79.19, Book Value: ₹482.88, and Debt-to-Equity: 7.74. The company's market cap stands at ₹15,930.03 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Natco Pharma Ltd stock performing today in the market?
Natco Pharma Ltd stock opened at ₹884.9 and is currently trading at ₹889, showing a gain of ₹5.50 (0.62%). The intraday high is ₹910 and low is ₹876.1. The trading volume stands at 10,20,729 shares, indicating strong market participation today.
08What is the P/E ratio of Natco Pharma Ltd and what does it indicate?
Natco Pharma Ltd has a Price-to-Earnings (P/E) ratio of 11.16, which means investors are willing to pay ₹11.16 for every ₹1 of earnings. With an EPS of ₹79.19, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Natco Pharma Ltd (NATCOPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy